Biolexis Therapeutics Unlocks a New Frontier in GLP-1 Receptor Activation
CryoEM Confirms a First-in-Class Allosteric Binding Mode, Validating MolecuLern™ AI-Driven Discovery LEHI, Utah, March 14, 2025 /PRNewswire/ — Biolexis Therapeutics has achieved…
